Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Xetra
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
94.25(c) 93.35(c) 93.7(c) 92.6(c) 91.85 Last
182 637 151 204 86 371 479 142 50 629 Volume
-2.53% -0.95% +0.37% -1.17% -0.81% Change
More quotes
Financials (EUR)
Sales 2018 65,0 M
EBIT 2018 -67,5 M
Net income 2018 -58,3 M
Finance 2018 383 M
Yield 2018 -
Sales 2019 66,0 M
EBIT 2019 -96,8 M
Net income 2019 -94,4 M
Finance 2019 245 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 39,4x
EV / Sales2019 40,9x
Capitalization 2 948 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications.It operates through the Proprietary Development and Partnered Discovery segments.The Proprietary Development segment combines proprietary research and development of therapeutic... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
09/22MORPHOSYS : InflaRx N.V. Announces Appointment of Jens Holstein to Board of Dire..
AQ
09/21MORPHOSYS AG : Notification and public disclosure of transactions by persons
EQ
09/21MORPHOSYS AG : Notification and public disclosure of transactions by persons
EQ
09/18GALAPAGOS : MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bri..
AQ
09/17MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived..
AC
09/17MORPHOSYS : and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived ..
EQ
09/17JOHNSON & JOHNSON : MorphoSys Announces that its Licensee Janssen has Reported T..
AQ
09/14GALAPAGOS : MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global..
AQ
09/13MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Stu..
AC
09/13MORPHOSYS : and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Stud..
PU
More news
Sector news : Biotechnology & Medical Research - NEC
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/21$663200 AG 1 director sold: A director at Morphosys Ag sold 8,927 shares at .. 
09/21InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors  
09/21MorphoSys AG: </td>  
09/21MorphoSys AG: </td>  
09/21Inflarx : 09-2018-InflaRx N.V. Announces Appointment of Jens Holstein to Boar.. 
More tweets
Qtime:58
News from SeekingAlpha
08/03MorphoSys AG reports Q2 results 
08/02MorphoSys AG (MPSYY) CEO Simon Moroney on Q2 2018 Results - Earnings Call Tra.. 
06/20MorphoSys (MOR) Presents At The JMP Securities Life Science Conference - Slid.. 
05/31ALEXION PHARMACEUTICALS : Clinical Progress, Acquisitions And The Competition (P.. 
05/03MorphoSys AG's (MPSYF) CEO Simon Moroney on Q1 2018 Results - Earnings Call T.. 
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 102 €
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Marc Cluzel Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Wendy S. Johnson Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG20.92%3 464
CELLTRION, INC.--.--%33 388
IQVIA HOLDINGS INC30.32%25 763
LONZA GROUP18.80%24 291
INCYTE CORPORATION-29.69%14 156
SEATTLE GENETICS, INC.45.35%12 348